ADMA Biologics Inc (NASDAQ:ADMA) has earned an average broker rating score of 1.33 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. ADMA Biologics’ rating score has improved by 20.4% from 90 days ago as a result of a number of analysts’ upgrades and downgrades.
Brokers have set a 1 year consensus price target of $7.63 for the company and are predicting that the company will post ($0.51) earnings per share for the current quarter, according to Zacks. Zacks has also assigned ADMA Biologics an industry rank of 161 out of 265 based on the ratings given to related companies.
Several brokerages have commented on ADMA. Maxim Group restated a “buy” rating and set a $8.00 price objective (down from $13.00) on shares of ADMA Biologics in a research report on Monday, December 11th. Raymond James Financial upgraded shares of ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a research report on Tuesday, November 14th.
Shares of ADMA Biologics (NASDAQ:ADMA) traded down $0.12 on Friday, reaching $3.57. 199,337 shares of the company’s stock traded hands, compared to its average volume of 142,019. ADMA Biologics has a 1-year low of $2.01 and a 1-year high of $5.74. The firm has a market capitalization of $95.18, a P/E ratio of -4.35 and a beta of 2.50. The company has a current ratio of 2.36, a quick ratio of 1.35 and a debt-to-equity ratio of 2.26.
In related news, insider Adam S. Grossman purchased 485,000 shares of the stock in a transaction dated Thursday, November 9th. The stock was bought at an average cost of $2.15 per share, for a total transaction of $1,042,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Eric I. Richman purchased 25,000 shares of the stock in a transaction dated Thursday, November 9th. The shares were bought at an average price of $2.15 per share, with a total value of $53,750.00. Following the completion of the acquisition, the director now directly owns 31,300 shares of the company’s stock, valued at approximately $67,295. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 526,500 shares of company stock valued at $1,131,975. Company insiders own 60.44% of the company’s stock.
An institutional investor recently raised its position in ADMA Biologics stock. Iguana Healthcare Management LLC lifted its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 276.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 565,000 shares of the biotechnology company’s stock after buying an additional 415,000 shares during the period. Iguana Healthcare Management LLC owned about 2.19% of ADMA Biologics worth $1,740,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 32.78% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://transcriptdaily.com/2018/01/13/1113937.html.
ADMA Biologics Company Profile
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.